| Ytd | ||
| 1y |
| Open | 46.99 | Prev Close | 46.99 | Low | 46.98 | High | 47.01 | Mkt Cap | 3.54B |
| Vol | 0.00 | Avg Vol | 5.85M | EPS | -3.41 | P/E | -13.78 | Forward P/E | -21.96 |
| Beta | 0.68 | Short Ratio | 1.46 | Inst. Own | 87.40% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 45.88 | 200-d Avg | 41.19 | 1yr Est | 47.00 |
SWTX News
Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size redu
– Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size re
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment
Immunome's lead asset, varegacestat, shows promising efficacy in desmoid tumors, with phase 3 toplin
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technolog
– If approved, nirogacestat will be the first and only therapy with marketing authorization in the E
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti,
SWTX wins CHMP backing for mirdametinib in NF1-PN. EU nod is expected in the third quarter of 2025.
– If approved, mirdametinib is expected to be the first and only therapy in the European Union with
SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $1.11 per share versus the Zacks C
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti,
The average of price targets set by Wall Street analysts indicates a potential upside of 42.3% in Sp
NEW YORK , April 28, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"),
NEW YORK , April 28, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating SpringWorks (Nasdaq: SWTX) for possible
German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t
On Friday, 1043 companies hit new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
On Monday, 721 companies achieved new lows for the year.